We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Guidance: Sponsors Should Define Role PRO Endpoint Plays in Clinical Trial
Guidance: Sponsors Should Define Role PRO Endpoint Plays in Clinical Trial
December 9, 2009
After three years of comment review, the FDA has issued a final guidance on patient-reported outcome (PRO) instruments submitted in applications.